BioRestorative Therapies Inc (NASDAQ:BRTX) Director John M. Desmarais acquired 80,000 shares of the company’s stock in a transaction on Monday, September 26th. The stock was acquired at an average cost of $3.00 per share, for a total transaction of $240,000.00. Following the completion of the purchase, the director now directly owns 455,000 shares of the company’s stock, valued at approximately $1,365,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

BioRestorative Therapies Inc (NASDAQ:BRTX) opened at 3.40 on Friday. The company’s 50 day moving average is $3.27 and its 200-day moving average is $3.69. BioRestorative Therapies Inc has a 52-week low of $2.61 and a 52-week high of $6.09. The company’s market capitalization is $14.56 million.

About BioRestorative Therapies

BioRestorative Therapies, Inc develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem).

5 Day Chart for NASDAQ:BRTX

Receive News & Stock Ratings for BioRestorative Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies Inc and related stocks with our FREE daily email newsletter.